Delstrigo Tablet, Film Coated
NDC Package 0006-5007-01

11-digit billing NDC: 00006500701 · Billing unit: EA · 30 EA per package

Package Information

Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets is dELSTRIGO® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, ORto replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0006-5007 and is authorized under FDA application NDA210807.

Identification & Billing

NDC Package Code
0006-5007-01
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
00006500701
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 2055813 - doravirine 100 MG / lamiVUDine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
  • RxCUI: 2055813 - doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
  • RxCUI: 2055813 - DORAVIRINE 100 MG / 3TC 300 MG / Tenofovir disoproxil fumarate 300 MG Oral Tablet
  • RxCUI: 2055813 - doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
  • RxCUI: 2055815 - Delstrigo 100 MG / 300 MG / 300 MG Oral Tablet

Clinical Specifications

Proprietary Name
Delstrigo
Non-Proprietary Name
Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate
Substance Name
Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
DELSTRIGO® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, ORto replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14)].

Regulatory & Marketing

Labeler Name
Merck Sharp & Dohme Llc
Product Type
Human Prescription Drug
FDA Application #
NDA210807
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-20-2018
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0006-5007-01 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Delstrigo, a human prescription drug labeled by Merck Sharp & Dohme Llc. This tablet, film coated is formulated for oral use and contains doravirine; lamivudine; tenofovir disoproxil fumarate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on July 20, 2018. The current certification is valid through December 31, 2027.

How is this Merck Sharp & Dohme Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00006500701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0006-5007-01
11-Digit CMS (5-4-2)
00006-5007-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.